Risk Factors of Thrombocytopenia In Chronic Kidney Disease And Hemodialysis Patients In Assiut University Hospitals
NCT ID: NCT06163144
Last Updated: 2023-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
132 participants
OBSERVATIONAL
2023-12-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Haemodialysis (HD) has been also identified as a potential cause of thrombocytopenia due to the interaction of dialysis membranes with platelets, triggering adhesion, aggregation, and activation.
Renal replacement therapy has improved in recent decades, particularly with the use of synthetic and highly biocompatible dialyzer membranes. During hemodialysis treatment, patients are exposed to a variety of components of the dialysis circuit and thrombocytopenia is not uncommon
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
End-stage renal disease (ESRD) is associated with abnormalities in both platelet count and function. Etiological factors contributing to thrombocytopenia in ESRD include uremia, blood loss, sepsis, and heparin treatment .
Haemodialysis (HD) has been also identified as a potential cause of thrombocytopenia due to the interaction of dialysis membranes with platelets, triggering adhesion, aggregation, and activation.
Renal replacement therapy has improved in recent decades, particularly with the use of synthetic and highly biocompatible dialyzer membranes. During hemodialysis treatment, patients are exposed to a variety of components of the dialysis circuit and thrombocytopenia is not uncommon Platelets, derived from megakaryocytes, are cell fragments present in the bloodstream. After release from the bone marrow, they are stored in the spleen for 24 to 48 hours. The spleen holds around 30% of circulating platelets, which typically have a lifespan of about 7 days. Platelets are removed from the bloodstream by macrophages .Platelet count in normal conditions range from 150,000 to 450,000/mm in peripheral blood.
Decreased platelet count occurs due to Reduced bone marrow production, increased platelet destruction, and other factors like drugs or alcohol consumption contribute to decreased platelet count. An alteration in the number of megakaryocytes indicates changes in destruction or production . Hemodialysis can lead to a 15% reduction in platelet count during a session, with subsequent recovery after treatment due to factors such as adhesion and complement activation, regardless of the dialysis membrane material Heparin-induced thrombocytopenia (HIT) is a condition that results in a prothrombotic state, particularly impacting patients with chronic kidney disease (CKD) undergoing hemodialysis (HD).Heparin induced thrombocytopenia (HIT) occurs when antibodies to platelet factor 4 (PF4) and heparin complexes bind to the Fragment Crystalloid γRIIA receptors (FcγRIIA) on platelets and monocytes to begin a hypercoagulable state that may cause thrombosis. Antibodies to PF4-heparin complexes are frequently detected in patients treated with unfractionated heparin. Orthopedic surgery, lower platelet count and higher titer of PF4-heparin antibodies have been shown to be concurrent factors that increase the risk of thrombosis in HIT. Hemodialysis, autoimmune diseases, gout, heart failure, intravenous route of heparin and\>5 days of heparin use were found to increase the risk of HIT diagnosis in medical patients . Substantial activation of platelets can occur in the course of hemodialysis. Platelet surface markers show evidence of platelet degranulation. Some activation occurs due to exposure of blood to the roller pump segment and microbubbles may play a rol Platelet activation seems to be reduced with reused dialyzers or with those containing synthetic versus cellulose membranes. Nevertheless, a substantial degree of platelet activation can be demonstrated with polysulfone and other synthetic membranes . the amount of activation may differ substantially among polysulfone membranes, depending on the manufacturer and the polyvinylpyrrolidone content. Platelet-platelet and platelet-leukocyte aggregates have been detected in the dialyzer blood outflow line and the consequences of these to the microcirculation are unknown. Typically, the platelet count decreases slightly during the first hour of dialysis, but mostly returns to initial values by the end of dialysis. Most recent cases of dialysis-associated thrombocytopenia have been with polysulfone membranes, especially polysulfone membranes sterilized by electron beam . Patients on HD also carry a greater risk of presenting with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, with a much higher prevalence in developing countries . Thrombocytopenia is one of the most widespread complications of chronic viral hepatitis (CVH). It appears secondary to hypersplenism in cirrhosis, immune-mediated mechanisms, shear stress, hyperfibrinolysis, bacterial translocation, sepsis, viral suppression of platelet production in the bone marrow, and decreased thrombopoietin. Thrombocytopenia interferes with interferon during antiviral treatment . hemolytic uremic syndrome commonly presents with the triad of microangiopathic hemolytic anemia, thrombocytopenia, and renal function impairment without an antecedent hemorrhagic diarrhea. Less known are extrarenal complications due to abnormal vascular permeability, although these are a major cause of morbidity and mortality for the patients. Furthermore, it is increasingly recognized that the disease may present with hypertension or renal function impairment with no or mild thrombocytopenia and microangiopathic hemolytic anemia . Awareness of the full spectrum of atypical hemolytic uremic syndrome may facilitate its diagnosis and treatment before serious complications or death occurs . Sepsis is a global health burden that needs intensive medical care. Thrombocytopenia in sepsis is well known to increase morbidity as well as mortality. Several studies have been performed both in animal models and in humans to understand the mechanism by which sepsis causes thrombocytopenia . Recent studies have shown that inhibiting thrombocytopenia improves outcomes in sepsis patients. Understanding these mechanisms to identify targets in use of newer treatment modalities besides using resuscitation measures, antibiotics and removal of thrombocytopenia inducing agent could potentially help us improve outcomes in sepsis .
Drug-induced thrombocytopenia occurs when certain medicines destroy platelets or interfere with the body's ability to make enough of them. There are two types of drug-induced thrombocytopenia: immune and non-immune. If a medicine causes the body to produce antibodies, which seek and destroy the platelets, the condition is called drug-induced immune thrombocytopenia. Heparin, a blood thinner, is the most common cause of drug induced immune thrombocytopenia If a medicine prevents bone marrow from making enough platelets, the condition is called drug-induced nonimmune thrombocytopenia. Chemotherapy drugs and a seizure medicine called valproic acid may lead to this problem. Other medicines that cause drug-induced thrombocytopenia include: Furosemide, gold, NSAIDs, penicillin, quinidine,quinine ,Ranitidine ,sulfonamide ,Statins Platelet count is regularly low in patients after multiple trauma, mainly due to blood loss and dilution.
Thrombopoietin is the main regulator of the circulating platelet mass. Under several clinical conditions an inverse correlation between thrombocytopenia and the circulating platelet mass was reported. Since platelets bind and internalize thrombocytopenia, a platelet-dependent regulation of thrombocytopenia was suggested. Thus, acute blood loss should be accompanied by elevated thrombocytopenia Will be measured serum thrombocytopenia, platelets, interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) . In multiple traumatized patients low platelet count is followed by a rapid increase in serum TPO. This fits into the concept of a feedback regulation between circulating TPO and platelet mass.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients CKD 4, CKD 5 non- HD
chronic kidney disease patients non hemodialysis
lab investigation
Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.
\*Automated cell counters
* Advia 2120 8 difference
* PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected.
Patients with ESRD on Regular -HD
end stage renal disease patients on hemodialysis
lab investigation
Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.
\*Automated cell counters
* Advia 2120 8 difference
* PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lab investigation
Platlets count by : advia cell counter principles . This flow cytometry-based system uses light scatter, differential white blood cell (WBC) lysis, and myeloperoxidase and oxazine 750 staining to provide a complete blood cell count, a WBC differential, and a reticulocyte count. A cyanide-free method is used to measure hemoglobin colorimetrically.
\*Automated cell counters
* Advia 2120 8 difference
* PLT , parameters , MPV . Prothrombin time , prothrombin concentration , International normalized ratio , activated partial thromboplastin time . BUN, Serum Createnin Serum Albumin Serum Ca, Ph, PTH HBsAg, HCV - Abs Erythrocyte sedimintation rate ,C- reactive protein . 2.Specific lab: C3 - C4, Anti Neuclear Antibody, Anti douple stranded DNA , if suspect lupus . PCR for HCV or HBV serum lactate if sepsis is suspected. drugs level if Addiction is suspected.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known patients with multiple myeloma and blood malignancies ( leukaemia ,, lymphoma
* Systemic lupus eryrthomatosis patients .Acute kidney injury patients .
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aya Ata Kamel
resident doctor at internal medicine department
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Shah R, Haddad N, Vachharajani TJ, Asif A, Agarwal A. Thrombocytopenia in ESRD patients: epidemiology, mechanisms and interventional nephrology perspective. Semin Dial. 2014 Nov-Dec;27(6):618-25. doi: 10.1111/sdi.12199. Epub 2014 Feb 24.
Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017 May 25;129(21):2864-2872. doi: 10.1182/blood-2016-11-709873. Epub 2017 Apr 17.
Arepally G, McKenzie SE, Jiang XM, Poncz M, Cines DB. Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood. 1997 Jan 15;89(2):370-5.
Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician. 2012 Mar 15;85(6):612-22.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
thrombocytopenia CKD
Identifier Type: -
Identifier Source: org_study_id